Altaire Recalled Millions Of OTC Eye Drops, Halted Production After Repeat GMP Problems Found
Executive Summary
“Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate,” FDA says. Warning submitted in March said falsifying data was found in making batch release decisions related to whether certain sterile ophthalmic drugs contained viable microorganisms.